PMID- 37220609
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230525
IS  - 2432-7026 (Electronic)
IS  - 2432-7026 (Linking)
VI  - 5
IP  - Spec Edition
DP  - 2022 Dec 23
TI  - Alternate Donor Transplantation.
PG  - S6-S14
LID - 10.31547/bct-2022-012 [doi]
AB  - There is a significant need for alternative donors other than full-matched 
      related or unrelated donors for allogeneic hematopoietic stem cell 
      transplantation, especially in the Asia Pacific, where donor registries are 
      smaller, and ethnicities are far more diverse. Both umbilical cord blood (UCB) 
      and haploidentical transplantation can be carried out despite significant human 
      leukocyte antigen (HLA) mismatches between patients and donors and help to meet 
      this need. There are advantages and disadvantages to UCB and haploidentical 
      transplantation, though enhancements in technology continue to improve outcomes 
      in both. Donor selection for these cell sources is dependent on the presence of 
      donor specific anti-HLA antibodies in the recipient's serum, degree and 
      characteristics of donor-recipient HLA mismatches, ABO compatibility. Specific to 
      haploidentical transplantation, additional factors like donor age, sex, 
      donor-recipient CMV serology as well as NK cell alloreactivity are also 
      important.
CI  - Copyright Ⓒ2022 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).
FAU - Hwang, William Yk
AU  - Hwang WY
AD  - National Cancer Centre Singapore.
AD  - Singapore General Hospital.
AD  - Duke-NUS Medical School Singapre.
FAU - Kongtim, Piyanuch
AU  - Kongtim P
AD  - Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of 
      Hematology-Oncology, Department of Medicine, University of California Irvine, CA, 
      USA.
FAU - Majhail, Navneet S
AU  - Majhail NS
AD  - Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA.
FAU - Yao, Ming
AU  - Yao M
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20221223
PL  - Japan
TA  - Blood Cell Ther
JT  - Blood cell therapy
JID - 9918333884906676
PMC - PMC10200364
OTO - NOTNLM
OT  - bone marrow
OT  - haploidentical
OT  - stem cell transplantation
OT  - umbilical cord blood
COIS- The authors declare that they have no relevant conflicts of interest. The 
      disclosure forms provided by the authors are available online. WHYK is a member 
      of the Editorial Board of Blood Cell Therapy and of the Board of Directors of the 
      Singapore Cord Blood Bank. He is not involved in the editorial evaluation or the 
      decision to accept this article for publication.
EDAT- 2023/05/23 19:09
MHDA- 2023/05/23 19:10
PMCR- 2022/12/23
CRDT- 2023/05/23 17:18
PHST- 2022/09/21 00:00 [received]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2023/05/23 19:10 [medline]
PHST- 2023/05/23 19:09 [pubmed]
PHST- 2023/05/23 17:18 [entrez]
PHST- 2022/12/23 00:00 [pmc-release]
AID - 10.31547/bct-2022-012 [doi]
PST - epublish
SO  - Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S6-S14. doi: 10.31547/bct-2022-012. 
      eCollection 2022 Dec 23.